Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
- PMID: 22622672
- DOI: 10.1002/ajh.23219
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
Abstract
A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
